This white paper examines how long-acting therapies could transform HIV treatment by reducing the burden of lifelong daily medication. Although modern single-tablet regimens provide strong safety, efficacy, and durable viral suppression, real-world adherence remains affected by pill fatigue, stigma, side effects, and treatment fatigue. Emerging oral and injectable therapies may extend dosing from daily to weekly, monthly, every two months, or twice yearly. These options could improve convenience and better align treatment with patient needs. However, adoption will depend on more than clinical performance. Patient selection, access, administration logistics, healthcare workflows, follow-up requirements, and support services will shape uptake. Daily oral therapy is expected to remain dominan

Join for free to read